The recently developed immune checkpoint inhibitors of such programmed death 1 (PD-1) inhibitors and programmed death-ligand 1 (PD-L1) inhibitors have revolutionized cancer immunotherapy [148]. This evidence concerns the gene CD274 and cancer.